Ensysce Biosciences Statistics
Share Statistics
Ensysce Biosciences has 1.30M shares outstanding. The number of shares has increased by 294.88% in one year.
| Shares Outstanding | 1.30M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 49.08% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.28M |
| Failed to Deliver (FTD) Shares | 507.19K |
| FTD / Avg. Volume | 27.91% |
Short Selling Information
The latest short interest is 6.35M, so 32.46% of the outstanding shares have been sold short.
| Short Interest | 6.35M |
| Short % of Shares Out | 32.46% |
| Short % of Float | 33.13% |
| Short Ratio (days to cover) | 0.12 |
Valuation Ratios
The PE ratio is -3.39 and the forward PE ratio is -0.74.
| PE Ratio | -3.39 |
| Forward PE | -0.74 |
| PS Ratio | 16.14 |
| Forward PS | 0.6 |
| PB Ratio | -111.5 |
| P/FCF Ratio | -3.34 |
| PEG Ratio | n/a |
Enterprise Valuation
Ensysce Biosciences Inc. has an Enterprise Value (EV) of 2.13M.
| EV / Earnings | -0.2 |
| EV / Sales | 0.96 |
| EV / EBITDA | -0.2 |
| EV / EBIT | -0.2 |
| EV / FCF | -0.2 |
Financial Position
The company has a current ratio of 0.69, with a Debt / Equity ratio of -2.65.
| Current Ratio | 0.69 |
| Quick Ratio | 0.69 |
| Debt / Equity | -2.65 |
| Total Debt / Capitalization | 160.71 |
| Cash Flow / Debt | -12.61 |
| Interest Coverage | -30.28 |
Financial Efficiency
Return on equity (ROE) is 32.87% and return on capital (ROIC) is -5268.73%.
| Return on Equity (ROE) | 32.87% |
| Return on Assets (ROA) | -3.92% |
| Return on Capital (ROIC) | -5268.73% |
| Revenue Per Employee | 318.65K |
| Profits Per Employee | -1.52M |
| Employee Count | 7 |
| Asset Turnover | 0.82 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -66.07% in the last 52 weeks. The beta is 0.64, so Ensysce Biosciences 's price volatility has been higher than the market average.
| Beta | 0.64 |
| 52-Week Price Change | -66.07% |
| 50-Day Moving Average | 6.81 |
| 200-Day Moving Average | 7.81 |
| Relative Strength Index (RSI) | 41.77 |
| Average Volume (20 Days) | 1.82M |
Income Statement
In the last 12 months, Ensysce Biosciences had revenue of $2.23M and earned -$10.61M in profits. Earnings per share was $-4.69.
| Revenue | 2.23M |
| Gross Profit | -5.36M |
| Operating Income | -10.72M |
| Net Income | -10.61M |
| EBITDA | -10.72M |
| EBIT | -10.72M |
| Earnings Per Share (EPS) | -4.69 |
Balance Sheet
The company has $1.12M in cash and $854.70K in debt, giving a net cash position of $268.91K.
| Cash & Cash Equivalents | 1.12M |
| Total Debt | 854.70K |
| Net Cash | 268.91K |
| Retained Earnings | -121.56M |
| Total Assets | 9.38M |
| Working Capital | 6.29M |
Cash Flow
In the last 12 months, operating cash flow was -$10.78M and capital expenditures $2, giving a free cash flow of -$10.78M.
| Operating Cash Flow | -10.78M |
| Capital Expenditures | 2 |
| Free Cash Flow | -10.78M |
| FCF Per Share | -4.76 |
Margins
Gross margin is -240.17%, with operating and profit margins of -480.52% and -475.81%.
| Gross Margin | -240.17% |
| Operating Margin | -480.52% |
| Pretax Margin | -476.4% |
| Profit Margin | -475.81% |
| EBITDA Margin | -480.52% |
| EBIT Margin | -480.52% |
| FCF Margin | -483.29% |
Dividends & Yields
ENSC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -83.01% |
| FCF Yield | -146.21% |
Analyst Forecast
Currently there are no analyst rating for ENSC.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Dec 6, 2024. It was a backward split with a ratio of 1:15.
| Last Split Date | Dec 6, 2024 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -19.31 |
| Piotroski F-Score | 2 |